Cholangiocarcinoma (CCA) is the second most common primary liver cancer and
associated with a dismal prognosis due to the lack of an efficient systemic therapy. In …

Cholangiocarcinomas (CCAs) are aggressive tumors arising along the biliary tract
epithelium, whose incidence and mortality are increasing. CCAs are highly desmoplastic …

Cholangiocarcinoma is characterized by a poor prognosis with limited treatment and
management options. Chemotherapy using gemcitabine with cisplatin is the only available …

Biliary tract cancers (BTCs) are a group of rare cancers that account for up to 3–5% of
cancer patients worldwide. BTCs include cholangiocarcinoma (CCA), gallbladder cancer …

Purpose Treatment of breast cancer (BC) by standard methods is effective in the early stage,
but ineffective in the advanced stage of disease. To develop an adoptive T cell therapy for …

Current treatment of cholangiocarcinoma (CCA)–a lethal bile duct cancer–is ineffective
because the disease is usually diagnosed at late and advanced stage. Thus, a novel …

Aim Cholangiocarcinoma is a malignant tumor originating from bile duct epithelium.
Currently, the treatment strategy is very limited and the prognosis is poor. Recent studies …

Abstract Treatment options for intrahepatic cholangiocarcinoma (iCCA), a highly malignant
tumor with poor prognosis, are limited. Recent developments in immunotherapy and …

Tobacco smoke exposure contributes to the global burden of communicable and chronic
diseases. To identify the immune cells affected by smoking, we use single-cell RNA …

Dendritic cell (DC)–based T-cell activation is an alternative immunotherapy in breast cancer.
The anti-programmed death ligand 1 (PD-L1) can enhance T-cell function. Nucleolin (NCL) …